课题基金 / 基金详情

DEXRAZOXANE, DOXORUBICIN & ESCALATING DOSES OF PACLITAXEL IN ADVANCED BREAST CA

DEXRAZOXANE, DOXORUBICIN & ESCALATING DOSES OF PACLITAXEL IN ADVANCED BREAST CA
右雷佐生、阿霉素
批准号：
6276961
负责人：
JAMES SPEYER
金额：
$2.03万
依托单位：
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-12-01 至 1998-11-30
来源：
https://reporter.nih.gov/project-details/6276961
关键词：
antineoplastics breast neoplasms clinical research clinical trial phase I combination chemotherapy doxorubicin drug screening /evaluation human subject human therapy evaluation neoplasm /cancer chemotherapy paclitaxel pharmacokinetics

项目摘要

项目成果

JAMES SPEYER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This Phase I trial will determine the maximum tolerable dose and response rate of paclitaxel that can be combined with doxorubicin and dexrazoxane with and without G-CSF. The effect of dexrazoxane on the pharmokinetics of paclitaxel used in combination with doxorubicin will be assessed. The maximum cumulative dose of doxorubicin that can be given when used in combination with dexrazoxane and paclitaxel will also be assessed.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Protocol Review and Monitoring
WEEKLY ONE HOUR PACLITAXEL IN REFRACTORY METASTATIC BREAST CANCER
WEEKLY ONE HOUR PACLITAXEL IN REFRACTORY METASTATIC BREAST CANCER
WEEKLY ONE HOUR PACLITAXEL IN REFRACTORY METASTATIC BREAST CANCER
海外基金